All In Biotech

Drug Trial Radar · NCT07357584

Efficacy and Safety of Doravirine in the Rapid Initiation

Efficacy and Safety of Doravirine in the Rapid Initiation of Highly Active Antiretroviral Therapy (HAART) in HIV-1positive Patients Without Prior Treatment

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Apr 30, 2028

Study completion Apr 30, 2028

Sponsor

Lead sponsor
Fundación HuéspedAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
MSD Pharmaceuticals LLC; Fundacion IDEAA
First posted
Jan 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Protocol title: "Efficacy and safety of doravirine in the rapid initiation of highly active antiretroviral therapy (HAART) in HIV-1positive patients without prior treatment."

Conditions

  • HIV-1-infection

Interventions

  • Doravirine / lamivudine/ Tenofovir Disoproxil Oral TabletDrug

    Pharmaceutical form: Oral tablets Unit dose concentration/dose level(s): 100/300/245 mg Administration instructions: Take one tablet once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the antiviral activity of DOR/3TC/TDF at week 48 in HIV patients without prior antiretroviral treatment, in a rapid initiation setting.Time frame: 48 Weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fundacion Huesped

    Buenos Aires, Argentina · Recruiting

  • Fundacion IDEAA -Infectologia de atencion ambulatoria

    Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.